{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T13:14:46Z","timestamp":1789391686361,"version":"build-2803163510"},"reference-count":32,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2019,12,2]],"date-time":"2019-12-02T00:00:00Z","timestamp":1575244800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background and aim: Oral mesalazine and sulfasalazine (SASP) are key drugs for treating ulcerative colitis (UC). The efficacy of switching from one of the several mesalazine formulations to another is largely unknown. This study assessed the efficacy of switching among three types of mesalazine formulation and SASP for UC therapy. Methods: UC patients receiving high-dose mesalazine\/SASP who switched to other formulations due to disease activity were considered eligible. Efficacy was evaluated 2, 6, and 12 months after switching. Results: A total of 106 switches in 88 UC patients were analyzed. The efficacy at 2 months after switching was observed in 23\/39 (59%) cases from any mesalazine formulation to SASP, in 18\/55 (33%) cases from one mesalazine to another, and in 2\/12 (17%) cases from SASP to any mesalazine formulation. Nine of 43 effective cases showed inefficacy or became intolerant post-switching. Delayed efficacy more than two months after switching was observed in four cases. Steroid-free remission was achieved in 42\/106 (39%) cases\u2014within 100 days in 35 of these cases (83%). Conclusions: Switching from mesalazine to SASP was effective in more than half of cases. The efficacy of switching between mesalazine formulations was lower but may be worth attempting in clinical practice from a safety perspective.<\/jats:p>","DOI":"10.3390\/jcm8122109","type":"journal-article","created":{"date-parts":[[2019,12,3]],"date-time":"2019-12-03T04:58:39Z","timestamp":1575349119000},"page":"2109","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Switching between Three Types of Mesalazine Formulation and Sulfasalazine in Patients with Active Ulcerative Colitis Who Have Already Received High-Dose Treatment with These Agents"],"prefix":"10.3390","volume":"8","author":[{"given":"Eriko","family":"Yasutomi","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sakiko","family":"Hiraoka","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shumpei","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shohei","family":"Oka","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mami","family":"Hirai","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Yamasaki","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiro","family":"Inokuchi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Kinugasa","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Takahara","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keita","family":"Harada","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba 260-0856, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Okada","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,12,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMra020831","article-title":"Inflammatory bowel disease","volume":"347","author":"Podolsky","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1053\/j.gastro.2018.12.008","article-title":"AGA Technical Review on the Management of Mild-to-Moderate Ulcerative Colitis","volume":"156","author":"Singh","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"j2505","DOI":"10.1136\/bmj.j2505","article-title":"Update on antitumor necrosis factor agents and other new drugs for inflammatory bowel disease","volume":"357","author":"Cohen","year":"2017","journal-title":"BMJ"},{"key":"ref_4","first-page":"CD000543","article-title":"Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis","volume":"4","author":"Wang","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_5","first-page":"CD000544","article-title":"Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis","volume":"5","author":"Wang","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"137","DOI":"10.4292\/wjgpt.v6.i4.137","article-title":"Mesalazine preparations for the treatment of ulcerative colitis: Are all created equal?","volume":"6","author":"Ye","year":"2015","journal-title":"World J. Gastrointest. Pharmacol. Ther."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1002\/cpt1972134539","article-title":"Absorption, metabolism, and excretion of salicylazosulfapyridine in man","volume":"13","author":"Schroeder","year":"1972","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1136\/gut.28.2.196","article-title":"Metabolism and urinary excretion of 5-aminosalicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract","volume":"28","author":"Myers","year":"1987","journal-title":"Gut"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1111\/j.1365-2036.2006.02861.x","article-title":"Comparison of the efficacy and safety of Eudragit-L-coated mesalazine tablets with ethylcellulose-coated mesalazine tablets in patients with mild to moderately active ulcerative colitis","volume":"23","author":"Gibson","year":"2006","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"255","DOI":"10.5217\/ir.2018.16.2.255","article-title":"Comparison of efficacy of once-daily multimatrix mesalazine 2.4 g\/day and 4.8 g\/day with other 5-aminosalicylic acid preparation in active ulcerative colitis: A randomized, double-blind study","volume":"16","author":"Ogata","year":"2018","journal-title":"Intest. Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e000103","DOI":"10.1136\/bmjgast-2016-000103","article-title":"Usefulness of sulfasalazine for patients with refractory-ulcerative colits","volume":"16","author":"Yoshino","year":"2016","journal-title":"BMJ Open Gastroenterol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1111\/apt.13408","article-title":"Development of interim patient-reported outcome measures for the assessment of ulcerative colitis disease activity in clinical trials","volume":"42","author":"Jairath","year":"2015","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1136\/bmj.298.6666.82","article-title":"Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: A randomised trial","volume":"298","author":"Rachmilewitz","year":"1989","journal-title":"BMJ"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1056\/NEJM199406303302601","article-title":"Cyclosporine in severe ulcerative colitis refractory to steroid therapy","volume":"330","author":"Lichtiger","year":"1994","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/ajg.2012.315","article-title":"Evaluation of mucosal healing of ulcerative colitis by a quantitative fecal immunochemical test","volume":"108","author":"Nakarai","year":"2013","journal-title":"Am. J. Gastroenterol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/ajg.2015.66","article-title":"Evaluation of Mucosal Healing in Ulcerative Colitis by Fecal Calprotectin vs. Fecal Immunochemical Test","volume":"110","author":"Takashima","year":"2015","journal-title":"Am. J. Gastroenterol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"142","DOI":"10.5009\/gnl17013","article-title":"Fecal immunochemical test and fecal calprotectin show different profiles in disease monitoring for ulcerative colitis","volume":"12","author":"Hiraoka","year":"2018","journal-title":"Gut Liver"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/S0016-5085(82)80075-9","article-title":"5-aminosalicylic acid in a slow-release preparation: Bioavailability, plasma level, and excretion in humans","volume":"83","author":"Rasmussen","year":"1982","journal-title":"Gastroenterology"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.3748\/wjg.15.1799","article-title":"Use of new once-daily 5-aminosalicylic acid preparations in the treatment of ulcerative colitis: Is there anything new under the sun?","volume":"15","author":"Lakatos","year":"2009","journal-title":"World J. Gastroenterol"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1002\/ibd.21193","article-title":"Direct comparison of two different mesalamine formulations for the induction of remission in patients with ulcerative colitis: A double-blind, randomized study","volume":"16","author":"Ito","year":"2010","journal-title":"Inflamm. Bowel. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1111\/j.1365-2036.2009.04117.x","article-title":"Clinical trial: Ulcerative colitis maintenance treatment with 5-ASA: A 1-year, randomized multicentre study comparing MMX with Asacol","volume":"30","author":"Prantera","year":"2009","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"342751","DOI":"10.1155\/2014\/342751","article-title":"Therapeutic efficacy of pH-dependent release formulation of mesalazine on active ulcerative colitis resistant to time-dependent release formulation: Analysis of fecal calprotectin concentration","volume":"2014","author":"Kawashima","year":"2014","journal-title":"BioMed Res. Int."},{"key":"ref_23","first-page":"613","article-title":"Efficacy of Pentasa tablets for the treatment of inflammatory bowel disease","volume":"102","author":"Wong","year":"2003","journal-title":"J. Formos. Med. Assoc."},{"key":"ref_24","first-page":"7","article-title":"Rescue therapy with sulfasalazine prior to immunosuppressive or biological agents in ulcerative colitis poorly controlled with mesalazine","volume":"36","author":"Busto","year":"2013","journal-title":"Gastroenterol. Hepatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/j.0954-6820.1942.tb06841.x","article-title":"Salazyopyrin, a new sulfanilamide preparation: A. Therapeutic results in rheumatic polyarthritis. B. Therapeutic results in ulcerative colitis. C. Toxic manifestations in treatment with sulfanilamide preparation","volume":"110","author":"Svartz","year":"1942","journal-title":"Acta Med. Scand."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0140-6736(65)90972-4","article-title":"Controlled trial of sulfasalazine in maintenance therapy for ulcerative colitis","volume":"1","author":"Misiewitz","year":"1965","journal-title":"Lancet"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1254\/jjp.54.121","article-title":"Inhibition of proliferative response and interleukin 2 productions by salazosulpapyridine and its metabolites","volume":"54","author":"Fujiwara","year":"1990","journal-title":"Jpn. J. Pharmacol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/0162-3109(90)90022-7","article-title":"The effect of salazosulfapyridine on the in vitro antibody production in murine spleen cells","volume":"19","author":"Fujiwara","year":"1990","journal-title":"Immunopharmacology"},{"key":"ref_29","first-page":"440","article-title":"Maturation of human dendritic cells as sulfasalazine target","volume":"42","author":"Matasic","year":"2001","journal-title":"Croat. Med. J."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1002\/1529-0131(200009)43:9<1941::AID-ANR4>3.0.CO;2-O","article-title":"The anti-inflammatory drug sulfasalazine inhibits tumor necrosis factor alpha expression in macrophages by inducing apoptosis","volume":"43","author":"Rodenburg","year":"2000","journal-title":"Arthritis Rheum."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1136\/gut.2003.037747","article-title":"Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine","volume":"53","author":"Kruis","year":"2004","journal-title":"Gut"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Fiorino, G., Sturniolo, G.C., Bossa, F., Cassinotti, A., Di Sabatino, A., Giuffrida, P., and Danese, S. (2019). A phase 2a, multicenter, randomized, double-blind, parallel-group, placebo-controlled trial of IBD98-M delayed-release capsules to induce remission in patients with active and mild to moderate ulcerative colitis. Cells, 8.","DOI":"10.3390\/cells8060523"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/8\/12\/2109\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:39:21Z","timestamp":1760189961000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/8\/12\/2109"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,2]]},"references-count":32,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["jcm8122109"],"URL":"https:\/\/doi.org\/10.3390\/jcm8122109","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,2]]}}}